Roche and C4 Therapeutics to advance degrader-antibody conjugates research
C4 Therapeutics will receive $20m upfront in addition to milestone payments, with a potential $1bn in additional milestones.
Drug Development
Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation
EverSea Medicines to acquire Hasten Biopharmaceuticals
Jeito Capital secures over $1.2bn for new biopharma investments
RoosterBio and MineBio team up to expand MSC solutions access in China
Halozyme and Vertex sign deal for Hypercon technology
Apnimed obtains up to $150m in funds for commercial launch of AD109
Neurocrine to acquire Soleno in $2.9bn transaction
